Molecular Design of Anticancer Drug Leads Based on Three-Dimensional Quantitative Structure-Activity Relationship

被引:22
作者
Huang, Xiao Yan [1 ]
Shan, Zhi Jie [1 ]
Zhai, Hong Lin [1 ]
Li, Li Na [1 ]
Zhang, Xiao Yun [1 ]
机构
[1] Lanzhou Univ, Coll Chem & Chem Engn, Lanzhou 730000, Peoples R China
关键词
MANIFEST ANTIPROLIFERATIVE ACTIVITY; NOVOBIOCIN ANALOGS; HSP90; INHIBITORS; CANCER; CHAPERONE; TARGET; HEAT-SHOCK-PROTEIN-90; GELDANAMYCIN; MODULATION; DOMAIN;
D O I
10.1021/ci2002236
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Heat shock protein 90 (Hsp90) takes part in the developments of several cancers. Novobiocin, a typically C-terminal inhibitor for Hsp90, will probably used as an important anticancer drug in the future. In this work, we explored the valuable information and designed new novobiocin derivatives based on a three-dimensional quantitative structure activity relationship (3D QSAR). The comparative molecular field analysis and comparative molecular similarity indices analysis models with high predictive capability were established, and their reliabilities are supported by the statistical parameters. Based on the several important influence factors obtained from these models, six new novobiocin derivatives with higher inhibitory activities were designed and confirmed by the molecular simulation with our models, which provide the potential anticancer drug leads for further research.
引用
收藏
页码:1999 / 2006
页数:8
相关论文
共 30 条
[21]   Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin [J].
Roe, SM ;
Prodromou, C ;
O'Brien, R ;
Ladbury, JE ;
Piper, PW ;
Pearl, LH .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (02) :260-266
[22]   The Hsp90 complex - A super-chaperone machine as a novel drug target [J].
Scheibel, T ;
Buchner, J .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (06) :675-682
[23]   MODULATION OF ANTITUMOR ALKYLATING-AGENTS BY NOVOBIOCIN, TOPOTECAN, AND LONIDAMINE [J].
SCHWARTZ, GN ;
TEICHER, BA ;
EDER, JP ;
HOLDEN, SA ;
ARA, G ;
HERMAN, TS ;
KORBUT, T .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1993, 32 (06) :455-462
[24]   Exploring the Binding Site of C-Terminal Hsp90 Inhibitors [J].
Sgobba, Miriam ;
Forestiero, Rosetta ;
Degliesposti, Gianluca ;
Rastelli, Giulio .
JOURNAL OF CHEMICAL INFORMATION AND MODELING, 2010, 50 (09) :1522-1528
[25]   HSP90 and the chaperoning of cancer [J].
Whitesell, L ;
Lindquist, SL .
NATURE REVIEWS CANCER, 2005, 5 (10) :761-772
[26]   The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors [J].
Whitesell, Luke ;
Bagatell, Rochelle ;
Falsey, Ryan .
CURRENT CANCER DRUG TARGETS, 2003, 3 (05) :349-358
[28]   Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone [J].
Workman, P .
CANCER DETECTION AND PREVENTION, 2002, 26 (06) :405-410
[29]   Hsp90 inhibitors identified from a library of novobiocin analogues [J].
Yu, XM ;
Shen, G ;
Neckers, L ;
Blake, H ;
Holzbeierlein, J ;
Cronk, B ;
Blagg, BSJ .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (37) :12778-12779
[30]   Synthesis and Evaluation of Noviose Replacements on Novobiocin That Manifest Antiproliferative Activity [J].
Zhao, Huiping ;
Kusuma, Bhaskar Reddy ;
Blagg, Brian S. J. .
ACS MEDICINAL CHEMISTRY LETTERS, 2010, 1 (07) :311-315